Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.44+0.04 (+0.74%)
At close: 04:00PM EDT
5.44 0.00 (0.00%)
After hours: 04:01PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 618.68M
Enterprise value 337.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)83.21
Price/book (mrq)1.45
Enterprise value/revenue 52.05
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.90
52-week change 331.72%
S&P500 52-week change 318.96%
52-week high 38.83
52-week low 31.63
50-day moving average 33.81
200-day moving average 34.34

Share statistics

Avg vol (3-month) 32.37M
Avg vol (10-day) 32.77M
Shares outstanding 5113.83M
Implied shares outstanding 6113.83M
Float 890.49M
% held by insiders 11.58%
% held by institutions 1109.57%
Shares short (15 July 2024) 420.29M
Short ratio (15 July 2024) 49.8
Short % of float (15 July 2024) 420.45%
Short % of shares outstanding (15 July 2024) 417.82%
Shares short (prior month 14 June 2024) 421.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,652.88%

Management effectiveness

Return on assets (ttm)-20.84%
Return on equity (ttm)-42.07%

Income statement

Revenue (ttm)6.48M
Revenue per share (ttm)0.06
Quarterly revenue growth (yoy)-96.70%
Gross profit (ttm)N/A
EBITDA -181.18M
Net income avi to common (ttm)-190.05M
Diluted EPS (ttm)-1.92
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)383.54M
Total cash per share (mrq)3.37
Total debt (mrq)102.07M
Total debt/equity (mrq)23.95%
Current ratio (mrq)8.69
Book value per share (mrq)3.74

Cash flow statement

Operating cash flow (ttm)-136.75M
Levered free cash flow (ttm)-51.7M